FDA published a company announcement of a nationwide voluntary recall of Lipofit Extreme Fat Burner 2.0 over undeclared fluoxetine and 2,4-dinitrophenol. Two undeclared substances, two very different kinds of failure.
Holland and Barrett's new own-label sachet is built on a fibre complex with a real open-access human trial behind it. That trial ran 150 minutes and never weighed anybody.
The FDA notified consumers about Esbelta Intense Loss and Esbelta Chupapanza Flat Belly on 18 August. This is not substitution and it is not underdosing — it is undeclared pharmaceutical ingredients, which no amount of label arithmetic would have caught.
Reported on 12 August: three more online weight-loss products added to the FDA's yellow oleander alert, which now runs to 25. The failure here is not a dose problem — it is that the plant in the capsule was not the plant on the label.
A July launch release for a probiotic-and-botanical weight-management capsule puts 'Supplement Facts' in its own headline. It names three bacterial strains and nine other ingredients, and attaches a number to none of them.
A famous stimulant brand is back for Europe with a fully disclosed panel. The disclosure is genuinely good; the case published for three of the inclusions is not.
A May ruling held that a weight-loss supplement's own name would be read as a health claim the advertiser could not show was authorised — and that an injection-pen comparison table put it in the territory of prescription medicines.
A staple of fat-burner formulas, and the one ingredient here where the most important published finding is about harm rather than benefit.